Trevi Therapeutics, Inc. – NASDAQ:TRVI

Add to watchlist

$7.33

+3.06

+71.66%

Market closed

Open in about 2 hours

+52.50%

month

+52.50%

quarter

+196.53%

year

Market Cap	357.46M
Enterprise value	21.37M

P/E	-4.26
EV/Sales	N/A
EV/EBITDA	-0.49
Price/Sales	N/A
Price/Book	0.31
PEG ratio	-0.29
EPS	-0.33

Revenue	N/A
EBITDA	-36.80M
Income	-33.56M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Trevi Therapeutics Stock Forecast

M Q Y

Last Year

Potential downside: -18.14%

Analysts Price target
Financials & Ratios estimates

Trevi Therapeutics, Inc. (NASDAQ:TRVI): Profit margin
Jun 2023	0	-7.14M
Sep 2023	0	-7.69M
Dec 2023	176K	-7.82M	-4443.75%
Mar 2024	0	-10.90M

Trevi Therapeutics, Inc. (NASDAQ:TRVI): Payout ratio
Payout ratio	0%

Trevi Therapeutics, Inc. (NASDAQ:TRVI): Dividend Yield
2019	5.09%
2020
2021
2022
2023

Trevi Therapeutics, Inc. (NASDAQ:TRVI): Debt to assets
Jun 2023	100977000	5.90M	5.85%
Sep 2023	95896000	6.28M	6.56%
Dec 2023	89403000	6.85M	7.67%
Mar 2024	78559000	6.22M	7.92%

Trevi Therapeutics, Inc. (NASDAQ:TRVI): Cash Flow
Jun 2023	-9.87M	19.63M	-7.66K
Sep 2023	-7.27M	17.98M	1.51K
Dec 2023	-6.35M	12.84M	-54
Mar 2024	-10.46M	-8.09M	-28K

Trevi Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Trevi Therapeutics, Inc. (NASDAQ:TRVI): Employee count
Aug 2023	22
Sep 2023	30
Oct 2023	30
Nov 2023	30
Dec 2023	25
Jan 2024	25
Feb 2024	25
Mar 2024	25
Apr 2024	25
May 2024	25
Jun 2024	25
Jul 2024	25

Trevi Therapeutics
Hedge Funds Holdings Q1 2023

13.98% -48.70%

of TRVI is owned by hedge funds

17 -19

hedge funds hold TRVI stock

9.02M -34.16M

shares is hold by hedge funds

TRVI hedge funds holdings changes

Trevi Therapeutics
Insider Trading

Trevi Therapeutics, Inc. (NASDAQ:TRVI): Insider trades (number of shares)
Period	Buy	Sel
Oct 2023	0	785
May 2024	0	87333
Aug 2024	0	52556
Sep 2024	0	61180

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	13 Dec 2024	GALLETTA CHRISTOPHER officer: See Remarks officer: See Remarks	Stock Option (right to buy)	15,000	$0.51	$7,665
Option	13 Dec 2024	GALLETTA CHRISTOPHER officer: See Remarks officer: See Remarks	Common Stock	15,000	$0.51	$7,665
Option	9 Sep 2024	GOOD JENNIFER L director, officer..	Common Stock	1,840	$1.43	$2,631
Sale	9 Sep 2024	GOOD JENNIFER L director, officer..	Common Stock	1,840	$3.04	$5,586
Option	9 Sep 2024	GOOD JENNIFER L director, officer..	Stock Option (right to buy)	1,840	$1.43	$2,631
Option	6 Sep 2024	GOOD JENNIFER L director, officer..	Common Stock	4,219	$1.43	$6,033
Sale	6 Sep 2024	GOOD JENNIFER L director, officer..	Common Stock	4,219	$3.03	$12,784
Option	6 Sep 2024	GOOD JENNIFER L director, officer..	Stock Option (right to buy)	4,219	$1.43	$6,033
Option	5 Sep 2024	GOOD JENNIFER L director, officer..	Common Stock	40,277	$1.43	$57,596
Sale	5 Sep 2024	GOOD JENNIFER L director, officer..	Common Stock	40,277	$3.11	$125,302

TRVI insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application METHODS OF ADMINISTERING NALBUPHINE Filling date: 9 May 2022 Issue date: 25 Aug 2022	9 May 2022	25 Aug 2022
Application	Application TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA Filling date: 24 Mar 2022 Issue date: 14 Jul 2022	24 Mar 2022	14 Jul 2022
Application	Application TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA Filling date: 23 Jul 2019 Issue date: 23 Jan 2020	23 Jul 2019	23 Jan 2020
Application	Application TREATMENT OF THE PRURITIC SYMPTOMS OF LIVER DISEASE Filling date: 10 Jul 2019 Issue date: 16 Jan 2020	10 Jul 2019	16 Jan 2020

Trevi Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 11 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 20 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 12 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 10 Aug 2023	Q2 2023 Earnings Call Transcript

TRVI earnings call transcripts

Trevi Therapeutics
Executives

Insider	Age	Since	Compensation
Ms. Jennifer L. Good (1965) Co-Founder, Chief Executive Officer, Pres & Director	60		$662,640
Dr. Thomas R. Sciascia (1953) Co-Founder & Chief Medical Officer	72		$476,250

Trevi Therapeutics
Latest News

Monday, 16 December 2024
07:36	Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering	prnewswire.com
Thursday, 12 December 2024
09:47	Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?	benzinga.com
07:30	Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough	prnewswire.com
Tuesday, 3 December 2024
16:05	Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine	prnewswire.com
Thursday, 21 November 2024
07:30	Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference	prnewswire.com
Wednesday, 6 November 2024
16:05	Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates	prnewswire.com
Wednesday, 30 October 2024
16:05	Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024	prnewswire.com
Monday, 21 October 2024
07:30	Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough	prnewswire.com
Tuesday, 15 October 2024
07:30	Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences	prnewswire.com
Thursday, 3 October 2024
16:05	Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program	prnewswire.com
Monday, 30 September 2024
17:30	Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.	prnewswire.com
Thursday, 26 September 2024
07:30	Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024	prnewswire.com
Friday, 6 September 2024
07:31	Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock	marketbeat.com
Wednesday, 4 September 2024
16:05	Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024	prnewswire.com
Wednesday, 28 August 2024
07:30	Trevi Therapeutics to Participate in September Investor and Medical Conferences	prnewswire.com
Sunday, 11 August 2024
01:28	Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript	seekingalpha.com
Thursday, 8 August 2024
16:05	Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance	prnewswire.com
Thursday, 1 August 2024
07:30	Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024	prnewswire.com
Tuesday, 2 July 2024
07:30	Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events	prnewswire.com
Saturday, 11 May 2024
13:56	Trevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call Transcript	Seeking Alpha
Thursday, 9 May 2024
07:30	Trevi Therapeutics to Participate in Upcoming Conferences	PRNewsWire
Wednesday, 1 May 2024
16:05	Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024	PRNewsWire
Thursday, 18 April 2024
10:56	Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now	Zacks Investment Research
Thursday, 4 April 2024
09:31	Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick	Zacks Investment Research
Wednesday, 20 March 2024
18:21	Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript	Seeking Alpha
Wednesday, 17 January 2024
13:01	Trevi Therapeutics, Inc. (TRVI) Upgraded to Strong Buy: Here's Why	Zacks Investment Research
Thursday, 30 November 2023
11:18	Down -38.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Trevi Therapeutics, Inc. (TRVI)	Zacks Investment Research
Tuesday, 14 November 2023
11:19	After Plunging -28.72% in 4 Weeks, Here's Why the Trend Might Reverse for Trevi Therapeutics, Inc. (TRVI)	Zacks Investment Research
Sunday, 12 November 2023
05:46	Trevi Therapeutics, Inc. (TRVI) Q3 2023 Earnings Call Transcript	Seeking Alpha
Wednesday, 11 October 2023
13:32	Trevi Therapeutics, Inc. (TRVI) Upgraded to Buy: Here's What You Should Know	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 2 Jan 2023

Organigram And Rounding Out My Tax Loss Selling Basket

Frequently Asked Questions (FAQ)

What's the price of Trevi Therapeutics stock today?

One share of Trevi Therapeutics stock can currently be purchased for approximately $7.33.
When is Trevi Therapeutics's next earnings date?

Unfortunately, Trevi Therapeutics's (TRVI) next earnings date is currently unknown.
Does Trevi Therapeutics pay dividends?

No, Trevi Therapeutics does not pay dividends.
How much money does Trevi Therapeutics make?

Trevi Therapeutics has a market capitalization of 357.46M.
What is Trevi Therapeutics's stock symbol?

Trevi Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TRVI".
What is Trevi Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Trevi Therapeutics?

Shares of Trevi Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Trevi Therapeutics's key executives?
Trevi Therapeutics's management team includes the following people:
- Ms. Jennifer L. Good Co-Founder, Chief Executive Officer, Pres & Director(age: 60, pay: $662,640)
- Dr. Thomas R. Sciascia Co-Founder & Chief Medical Officer(age: 72, pay: $476,250)
Is Trevi Therapeutics founder-led company?

Yes, Trevi Therapeutics is a company led by its founders Ms. Jennifer L. Good and Dr. Thomas R. Sciascia.
How many employees does Trevi Therapeutics have?

As Jul 2024, Trevi Therapeutics employs 25 workers.
When Trevi Therapeutics went public?

Trevi Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 7 May 2019.
What is Trevi Therapeutics's official website?

The official website for Trevi Therapeutics is trevitherapeutics.com.
Where are Trevi Therapeutics's headquarters?

Trevi Therapeutics is headquartered at 195 Church Street, New Haven, CT.
How can i contact Trevi Therapeutics?

Trevi Therapeutics's mailing address is 195 Church Street, New Haven, CT and company can be reached via phone at +20 3 3042499.
What is Trevi Therapeutics stock forecast & price target?

Based on 2 Wall Street analysts` predicted price targets for Trevi Therapeutics in the last 12 months, the avarage price target is $6. The average price target represents a -18.14% change from the last price of $7.33.

Trevi Therapeutics, Inc.

trevitherapeutics.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

+20 3 3042499

195 Church Street
New Haven, CT 06510

CIK: 0001563880
ISIN: US89532M1018
CUSIP: 89532M101